C
11.22
-0.49 (-4.18%)
| Previous Close | 11.71 |
| Open | 11.65 |
| Volume | 1,337,963 |
| Avg. Volume (3M) | 2,004,131 |
| Market Cap | 835,095,616 |
| Price / Earnings (TTM) | 44.88 |
| Price / Earnings (Forward) | 13.19 |
| Price / Sales | 8.49 |
| Price / Book | 7.35 |
| 52 Weeks Range | |
| Earnings Date | 12 Aug 2025 - 18 Aug 2025 |
| Profit Margin | 20.81% |
| Operating Margin (TTM) | 51.49% |
| Diluted EPS (TTM) | 0.250 |
| Total Debt/Equity (MRQ) | 0.41% |
| Current Ratio (MRQ) | 4.21 |
| Operating Cash Flow (TTM) | -13.57 M |
| Levered Free Cash Flow (TTM) | -21.07 M |
| Return on Assets (TTM) | 8.31% |
| Return on Equity (TTM) | 19.87% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | CorMedix Inc. | Bullish | Bullish |
AIStockmoo Score
0.5
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | 0.50 |
|
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company’s focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 1.19% |
| % Held by Institutions | 37.18% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 20.00 (HC Wainwright & Co., 78.25%) | Buy |
| 20.00 (Needham, 78.25%) | Buy | |
| Median | 18.50 (64.88%) | |
| Low | 15.00 (D. Boral Capital, 33.69%) | Buy |
| Average | 18.00 (60.43%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 14.55 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 30 Jun 2025 | 20.00 (78.25%) | Buy | 12.32 |
| Needham | 24 Jun 2025 | 20.00 (78.25%) | Buy | 15.72 |
| 07 May 2025 | 15.00 (33.69%) | Buy | 11.68 | |
| D. Boral Capital | 23 Jun 2025 | 15.00 (33.69%) | Buy | 16.56 |
| 06 May 2025 | 15.00 (33.69%) | Buy | 11.16 | |
| RBC Capital | 20 Jun 2025 | 17.00 (51.52%) | Buy | 13.61 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 27 Jun 2025 | Announcement | CorMedix Inc. Announces Pricing of Public Offering of Common Stock |
| 26 Jun 2025 | Announcement | CorMedix Inc. Announces Proposed Public Offering of Common Stock |
| 23 Jun 2025 | Announcement | CorMedix inc. Announces Customer Implementation |
| 30 May 2025 | Announcement | CorMedix Inc. To Participate In The Jefferies Global Healthcare Conference |
| 15 May 2025 | Announcement | CorMedix Inc. to Participate in the RBC Global Healthcare Conference |
| 06 May 2025 | Announcement | CorMedix Inc. Reports First Quarter 2025 Financial Results and Provides Business Update |
| 29 Apr 2025 | Announcement | CorMedix Inc. to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 6, 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |